AllergyTalk

Episode 34: Are Nasal Polyps an Autoimmune Disease?

Originally Recorded 4/18/2023
 
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
 
Combined ICS/SBA Reduces Asthma Exacerbations
 
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
CRSwNP Patients have Impaired Sense of Smell and Taste
 
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
 
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
 
Anti-dsDNA IgG May Predict Nasal Polyp Recurrence
 
Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
 
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Joshi has the following disclosures:
Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
Clinical trial funding: GlaxoSmithKline Sanofi
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 33: Are We Testing for Hymenoptera Backwards?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Vivan Hernandez-Trujillo, MD from Nicklaus Children’s Hospital in Miami, Florida where we review the July-Aug 2022 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Combining Discordant Serum IgE and Skin Testing Improves Diagnostic and Therapeutic Accuracy for Hymenoptera Venom Hypersensitivity Immunotherapy.
Safety of Live Attenuated Influenza Vaccine in Children With Asthma.
Obesity alters pathology and treatment response in inflammatory disease.
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Hernandez-Trujillo: 
Speaker Takeda, CSL
Advisory boards Takeda, Regeneron, Sanofi
Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network
Dr. Fineman:
Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 27: How Important Is Family History in Infant Peanut Allergy?

Originally recorded 11/24/21
For today’s episode we will be reviewing three articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Is Alpha-Gal Really a Problem in Patients with Food Allergy?Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018.
Family history alone isn’t a Risk Factor for Peanut AllergyAge and eczema severity, but not family history, are major risk factors for peanut allergy in infancy.
Peripheral eosinophil counts: a moving targetVariability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma.
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Omalizumab for Food Allergy Part 2: Implementation Into Practice

Welcome to a special 2 part episode of Allergytalk!
On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Chinthrajah has consulted for Genentech and Novartis.
Dr. Vickery has consulted for Genentech and Novartis

Omalizumab for Food Allergy Part 1 : Reviewing the Evidence

Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a 2 part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study that led to this FDA indication. In Part II, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Wood has consulted for Genentech.
Dr. Vickery has consulted for Genentech and Novartis

Episode 29: A New Asthma Biologic, Biomarkers for AERD, mHealth for Asthma Nov/Dec 2021

For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts
 
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
 
Predicting Response to Aspirin Therapy in NSAID-ERD
 
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.
 
Can Technology Aid in Asthma Therapy Adherence?
 
The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial.
 
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 28: Is IBS a Type of Food Allergy? Nov/Dec 2021

For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
 
Metabolic Changes During Anaphylaxis Vary by Triggers and Severity
 
Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers.
 
Is IBS Caused by Local Food Allergy in the Intestine?
 
Local immune response to food antigens drives meal-induced abdominal pain.
 
Biologics: To Stop or Not to Stop, That Is the Question
 
Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.
 
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 26: Do Airborne Peanuts Cause Allergic Reactions? July/Aug 2021

For today’s episode we will be reviewing articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
When an asthma patient doesn’t respond to biologic, what should we do?
Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.
Can we reduce lung function loss in asthma?
Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.
Airborne peanut doesn’t cause clinical significant reactions
Peanuts in the air - clinical and experimental studies.
 
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, Alladapt, Novartis

Episode 25: Is Cefazolin Safe in Penicillin Allergic Patients? May/June 2021

For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.
Cefazolin Should Be Used in Most Penicillin Allergic Patients
Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin: A Systematic Review and Meta-analysis.
 
Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine
 
Cardiovascular changes during peanut-induced allergic reactions in human subjects.
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

AllergyTalk Episode 32: How Does the Atopic March Differ in Black and White Children?

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Hernandez-Trujillo: 
Speaker Takeda, CSL
Advisory boards Takeda, Regeneron, Sanofi
Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst